Entrada Therapeutics, Inc. (TRDA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.13-0.56%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TRDA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 4.7 | 25.4 | 210.8 | 129.0 | — | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 140.7 | 142.3 | 125.3 | 99.9 | 66.6 | 35.9 | 21.1 |
| Operating Income | (176.5) | (157.9) | 47.0 | (3.2) | (97.2) | (51.1) | (26.7) |
| Earnings from Continuing Operations | |||||||
| Asset Writedown | — | — | — | — | — | 0.0 | 0.0 |
| Income Tax Expense | 0.8 | 0.9 | 0.9 | 18.7 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (165.8) | (143.8) | 65.6 | (6.7) | (94.6) | (51.2) | (26.5) |
| Per Share | |||||||
| Basic EPS | (3.93) | (3.47) | 1.76 | (0.20) | (3.02) | (8.16) | (24.00) |
| Diluted EPS | (3.93) | (3.47) | 1.68 | (0.20) | (3.02) | (8.16) | (24.00) |
| Revenue per Share | 0.11 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 42.2 | 41.4 | 37.3 | 33.1 | 31.3 | 6.3 | 1.1 |
| Diluted Weighted Avg Shares | 42.2 | 41.4 | 39.0 | 33.1 | 31.3 | 6.3 | 1.1 |
| Supplemental | |||||||
| EBIT | (176.5) | (157.9) | 47.0 | (3.2) | (97.2) | (51.1) | (26.7) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.